drugset / Trial / NCT06974825
A Study of BGM0504 in Chinese Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of BGM0504 in Chinese patients with Type 2 Diabetes.
Timeline
- Start
- 2023-08-30
- Primary completion
- 2024-08-13
- Completion
- 2024-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGM0504 | Unknown | 5 mg | Subcutaneous |
| Subject | BGM0504 | Unknown | 10 mg | Subcutaneous |
| Subject | BGM0504 | Unknown | 15 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 1 mg | Subcutaneous |